Company intelligence / Profile preview

Azur Pharma

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

Azur Pharma was a profitable specialty pharmaceutical company that merged with Jazz Pharmaceuticals in 2012. The company had a diverse portfolio of products in CNS and women's health areas with approximately $95-100 million in net sales in 2011.

Therapeutic areas: Women's HealthPsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

NIRAVAM

Commercial

Indications: Central nervous system disorders

3 more assets in the full pipeline.

Request access →

Partnerships

Jazz Pharmaceuticals

Beyond the preview

Go deeper on Azur Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Azur Pharma.

Explore the full profile